In a report released on July 23, from UBS maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, with a price target o...
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has an analyst consensus of Strong Buy, with a price target consensus of HK$37.87.
Based on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$375.38 million and a GAAP net loss of HK$136.31 million. In comparison, last year the company earned a revenue of HK$158.01 million and had a GAAP net loss of HK$365.25 million
In a report released on June 17, from UBS maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, with a…
In a report released on May 27, from Citi maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, with a…
In a report released on July 2, from China Merchants Securities maintained a Buy rating on UBTECH ROBOTICS CORP LTD Class H,…
In a report released yesterday, from Citi maintained a Buy rating on UBTECH ROBOTICS CORP LTD Class H, with a price target of…
In a report released on June 25, from UBS maintained a Buy rating on CanSino Biologics, Inc. Class H, with a price target of…
In a report released on July 2, from UBS maintained a Buy rating on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H, with a…
